ARROWHEAD PHARMACEUTICALS IN (ARWR) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:ARWR • US04280A1007

73 USD
+3.67 (+5.29%)
At close: Feb 2, 2026
73.15 USD
+0.15 (+0.21%)
After Hours: 2/2/2026, 8:00:00 PM
Fundamental Rating

4

Overall ARWR gets a fundamental rating of 4 out of 10. We evaluated ARWR against 524 industry peers in the Biotechnology industry. Both the profitability and the financial health of ARWR get a neutral evaluation. Nothing too spectacular is happening here. While showing a medium growth rate, ARWR is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • ARWR had negative earnings in the past year.
  • ARWR had a positive operating cash flow in the past year.
  • In the past 5 years ARWR always reported negative net income.
  • In multiple years ARWR reported negative operating cash flow during the last 5 years.
ARWR Yearly Net Income VS EBIT VS OCF VS FCFARWR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200M -400M -600M

1.2 Ratios

  • The Return On Assets of ARWR (-0.12%) is better than 88.36% of its industry peers.
  • ARWR has a better Return On Equity (-0.35%) than 89.89% of its industry peers.
  • ARWR's Return On Invested Capital of 4.83% is amongst the best of the industry. ARWR outperforms 91.60% of its industry peers.
Industry RankSector Rank
ROA -0.12%
ROE -0.35%
ROIC 4.83%
ROA(3y)-26.51%
ROA(5y)-24.96%
ROE(3y)-133.1%
ROE(5y)-95.59%
ROIC(3y)N/A
ROIC(5y)N/A
ARWR Yearly ROA, ROE, ROICARWR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300

1.3 Margins

  • The Operating Margin of ARWR (11.86%) is better than 92.18% of its industry peers.
  • The Profit Margin and Gross Margin are not available for ARWR so they could not be analyzed.
Industry RankSector Rank
OM 11.86%
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARWR Yearly Profit, Operating, Gross MarginsARWR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10K -20K -30K -40K

More info and screens

6

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ARWR is destroying value.
  • The number of shares outstanding for ARWR has been increased compared to 1 year ago.
  • ARWR has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for ARWR has been reduced compared to a year ago.
ARWR Yearly Shares OutstandingARWR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
ARWR Yearly Total Debt VS Total AssetsARWR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • An Altman-Z score of 6.31 indicates that ARWR is not in any danger for bankruptcy at the moment.
  • ARWR's Altman-Z score of 6.31 is fine compared to the rest of the industry. ARWR outperforms 75.57% of its industry peers.
  • The Debt to FCF ratio of ARWR is 3.97, which is a good value as it means it would take ARWR, 3.97 years of fcf income to pay off all of its debts.
  • With an excellent Debt to FCF ratio value of 3.97, ARWR belongs to the best of the industry, outperforming 92.18% of the companies in the same industry.
  • ARWR has a Debt/Equity ratio of 1.25. This is a high value indicating a heavy dependency on external financing.
  • ARWR has a Debt to Equity ratio of 1.25. This is in the lower half of the industry: ARWR underperforms 75.95% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.25
Debt/FCF 3.97
Altman-Z 6.31
ROIC/WACC0.58
WACC8.33%
ARWR Yearly LT Debt VS Equity VS FCFARWR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M -400M 600M -600M

2.3 Liquidity

  • A Current Ratio of 4.86 indicates that ARWR has no problem at all paying its short term obligations.
  • ARWR has a Current ratio of 4.86. This is comparable to the rest of the industry: ARWR outperforms 55.92% of its industry peers.
  • A Quick Ratio of 4.86 indicates that ARWR has no problem at all paying its short term obligations.
  • The Quick ratio of ARWR (4.86) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.86
Quick Ratio 4.86
ARWR Yearly Current Assets VS Current LiabilitesARWR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

More info and screens

6

3. Growth

3.1 Past

  • ARWR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 98.40%, which is quite impressive.
  • The Revenue has grown by 23258.15% in the past year. This is a very strong growth!
  • ARWR shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 56.63% yearly.
EPS 1Y (TTM)98.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.86%
Revenue 1Y (TTM)23258.15%
Revenue growth 3Y50.53%
Revenue growth 5Y56.63%
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 114.38% on average over the next years. This is a very strong growth
  • ARWR is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.62% yearly.
EPS Next Y-4191.43%
EPS Next 2Y-666.18%
EPS Next 3Y-250.11%
EPS Next 5Y114.38%
Revenue Next Year-47.26%
Revenue Next 2Y-40.31%
Revenue Next 3Y-13.3%
Revenue Next 5Y14.62%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ARWR Yearly Revenue VS EstimatesARWR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B
ARWR Yearly EPS VS EstimatesARWR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 -5 10

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ARWR. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ARWR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ARWR Price Earnings VS Forward Price EarningsARWR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -200 -400 -600 -800

4.2 Price Multiples

  • ARWR's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ARWR is cheaper than 90.08% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of ARWR indicates a rather cheap valuation: ARWR is cheaper than 92.56% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 63.19
EV/EBITDA 73
ARWR Per share dataARWR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

  • A cheap valuation may be justified as ARWR's earnings are expected to decrease with -250.11% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-666.18%
EPS Next 3Y-250.11%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for ARWR!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ARROWHEAD PHARMACEUTICALS IN

NASDAQ:ARWR (2/2/2026, 8:00:00 PM)

After market: 73.15 +0.15 (+0.21%)

73

+3.67 (+5.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-25
Earnings (Next)02-05
Inst Owners84.75%
Inst Owner Change-1.53%
Ins Owners3.83%
Ins Owner Change-0.65%
Market Cap9.91B
Revenue(TTM)829.45M
Net Income(TTM)-1.63M
Analysts79
Price Target77.6 (6.3%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.1%
Min EPS beat(2)-20.51%
Max EPS beat(2)26.7%
EPS beat(4)2
Avg EPS beat(4)314.12%
Min EPS beat(4)-211.36%
Max EPS beat(4)1461.66%
EPS beat(8)2
Avg EPS beat(8)64.89%
EPS beat(12)3
Avg EPS beat(12)32.54%
EPS beat(16)4
Avg EPS beat(16)33.96%
Revenue beat(2)2
Avg Revenue beat(2)28.89%
Min Revenue beat(2)14.81%
Max Revenue beat(2)42.98%
Revenue beat(4)3
Avg Revenue beat(4)410.31%
Min Revenue beat(4)-96.63%
Max Revenue beat(4)1680.09%
Revenue beat(8)3
Avg Revenue beat(8)156.63%
Revenue beat(12)4
Avg Revenue beat(12)105.73%
Revenue beat(16)5
Avg Revenue beat(16)73.56%
PT rev (1m)23.01%
PT rev (3m)57.48%
EPS NQ rev (1m)-3.07%
EPS NQ rev (3m)-25.95%
EPS NY rev (1m)-4.21%
EPS NY rev (3m)-17.77%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.41%
Revenue NY rev (1m)-3.44%
Revenue NY rev (3m)2.9%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 11.95
P/FCF 63.19
P/OCF 55.22
P/B 21.27
P/tB 21.59
EV/EBITDA 73
EPS(TTM)-0.08
EYN/A
EPS(NY)-3.43
Fwd EYN/A
FCF(TTM)1.16
FCFY1.58%
OCF(TTM)1.32
OCFY1.81%
SpS6.11
BVpS3.43
TBVpS3.38
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -0.12%
ROE -0.35%
ROCE 8.27%
ROIC 4.83%
ROICexc 21.1%
ROICexgc 21.65%
OM 11.86%
PM (TTM) N/A
GM N/A
FCFM 18.91%
ROA(3y)-26.51%
ROA(5y)-24.96%
ROE(3y)-133.1%
ROE(5y)-95.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.6
Health
Industry RankSector Rank
Debt/Equity 1.25
Debt/FCF 3.97
Debt/EBITDA 4.76
Cap/Depr 94.73%
Cap/Sales 2.73%
Interest Coverage 5176.11
Cash Conversion 146.84%
Profit Quality N/A
Current Ratio 4.86
Quick Ratio 4.86
Altman-Z 6.31
F-Score6
WACC8.33%
ROIC/WACC0.58
Cap/Depr(3y)756.37%
Cap/Depr(5y)612.23%
Cap/Sales(3y)1353.35%
Cap/Sales(5y)819.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)98.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.86%
EPS Next Y-4191.43%
EPS Next 2Y-666.18%
EPS Next 3Y-250.11%
EPS Next 5Y114.38%
Revenue 1Y (TTM)23258.15%
Revenue growth 3Y50.53%
Revenue growth 5Y56.63%
Sales Q2Q%N/A
Revenue Next Year-47.26%
Revenue Next 2Y-40.31%
Revenue Next 3Y-13.3%
Revenue Next 5Y14.62%
EBIT growth 1Y116.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-482.54%
EBIT Next 3Y-119.02%
EBIT Next 5Y45.74%
FCF growth 1Y125.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y138.79%
OCF growth 3YN/A
OCF growth 5YN/A

ARROWHEAD PHARMACEUTICALS IN / ARWR FAQ

What is the fundamental rating for ARWR stock?

ChartMill assigns a fundamental rating of 4 / 10 to ARWR.


What is the valuation status of ARROWHEAD PHARMACEUTICALS IN (ARWR) stock?

ChartMill assigns a valuation rating of 2 / 10 to ARROWHEAD PHARMACEUTICALS IN (ARWR). This can be considered as Overvalued.


What is the profitability of ARWR stock?

ARROWHEAD PHARMACEUTICALS IN (ARWR) has a profitability rating of 4 / 10.


How financially healthy is ARROWHEAD PHARMACEUTICALS IN?

The financial health rating of ARROWHEAD PHARMACEUTICALS IN (ARWR) is 6 / 10.


Can you provide the expected EPS growth for ARWR stock?

The Earnings per Share (EPS) of ARROWHEAD PHARMACEUTICALS IN (ARWR) is expected to decline by -4191.43% in the next year.